IJMS MDPI Submission Guide: Requirements, Formatting and What Editors Want

Most IJMS submission guidance explains MDPI logistics: templates, Susy upload, APC, publication ethics, and data availability statements. That is useful, but it mostly repeats official instructions.

This guide gives you the decision layer beyond the official checklist: whether the abstract, methods, figures, tables, and conclusion prove a molecular science contribution rather than a general biomedical, clinical, or engineering claim. For IJMS, the common pre-review failure is not only missing a file. It is submitting a paper where the molecular mechanism, reagent trail, cell-line authentication, statistical design, or data-availability language is too incomplete for reproducibility assessment.

This update spot-checked recent IJMS article records to keep the guidance grounded in the current issue mix, including DOI examples 10.3390/ijms27083516, 10.3390/ijms27083536, and 10.3390/ijms27083352.

If you want the quick pre-upload call, run an IJMS MDPI submission readiness check before opening the MDPI submission system.

Source: IJMS Instructions for Authors, JCR 2024, accessed May 2026.

IJMS editorial workflow at MDPI SuSy (MDPI SuSy submission system) runs on MDPI's standard fast-track cadence. Editors screen for methodological completeness, molecular-science centrality, and reproducibility evidence in the first read.

Day 1-3: Receipt and tech-check

SuSy confirms file integrity, the 200-word abstract limit, the MDPI Word / LaTeX template usage, ORCID for corresponding author, the data availability statement, the AI-use declaration, and the 120 MB upload cap. Abstracts over 200 words or missing data availability statement get a technical-return.

Day 3-7: Section-editor assignment

A section editor (Biochemistry, Molecular Biology, Cell Biology, Immunology, Structural Biology, Bioinformatics, Genetics) takes the paper. The scope read decides whether the contribution is broad molecular-science work or better routed to sister MDPI journals (Cells, Biomolecules, Cancers, Antioxidants) or to specialty venues (J. Biol. Chem., Cell Reports, EMBO J.).

Week 1-3: Reviewer invitation and reports

Single-anonymous peer review with >=2 reviewers (mandatory). IJMS reviewers consistently flag underpowered experiments (nless than 3) and missing statistical-test specification. Reviewer turnaround targets 2 weeks per round.

Day 15-30 (median): First decision

Reject / major revision / minor revision / accept. MDPI's 15-30-day median is faster than any subscription venue. Revisions returned within the requested window typically reach second decision in 1-2 weeks; accepted papers publish online within 3-5 days of acceptance.

Editors screen IJMS uploads against the following artifacts at MDPI SuSy tech-check (MDPI SuSy submission system). Missing any of the first five triggers a technical-return rather than substantive desk review.

The required artifacts are the cover letter (with molecular-science-centrality framing and any prior-rejection / preprint disclosure), the manuscript file in the MDPI IJMS Word or LaTeX template, the abstract (no more than 200 words; strictly enforced), the keywords (3-6 recommended), the author contributions statement (CRediT taxonomy), the conflicts of interest declaration, the funding statement and source listing, the data availability statement (mandatory;

public repository deposits strongly preferred for sequencing, structural, proteomics data), the institutional review board statement (for human-subjects or animal work), the ethics approval and consent statement (where applicable), the suggested reviewers (>=3 non-conflicted experts; MDPI uses these in reviewer invitation), the supplementary materials (within the 120 MB upload cap), and the author biography (300-1,500 characters, encouraged for SciProfiles).

ORCID identifiers are required for the corresponding author and encouraged for co-authors.

Official sources set the requirements, but the remaining question is manuscript fit. The review tells you whether your paper clears the IJMS MDPI fit check before upload, especially around molecular-science contribution weaker than the clinical or applied promise, methods look complete but reproducibility details are not traceable, and special-issue speed or APC logic outruns journal-fit discipline. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

For manuscripts targeting International Journal of Molecular Sciences, three patterns generate the most consistent desk-screen failures before authors reach the fast MDPI review path. Official guidance explains the upload checklist, article types, template expectations, ethics declarations, data availability statement, and APC process. The author decision layer is harder: whether the title, abstract, methods, figures, cover letter, supplementary files, references, and repository plan prove that the work is molecular-science-centered enough for IJMS rather than simply formatted for the MDPI portal.

Molecular-science contribution weaker than the clinical or applied promise

Across IJMS-targeted manuscripts, the most common failure pattern is a paper whose abstract promises a disease, therapy, biomarker, environmental, or engineering advance while the molecular-science contribution remains secondary. IJMS can publish across biochemistry, molecular biology, cell biology, immunology, structural biology, genetics, bioinformatics, and molecular medicine, but the editor still needs the molecular component to be the protagonist.

Weak submissions often have a title and abstract that emphasize clinical or applied value, figures that show phenotype or performance before mechanism, and a cover letter that says the work is timely without explaining what molecular understanding improved.

The fix is not a sentence of molecular vocabulary. The abstract should name the pathway, interaction, molecular axis, structural feature, assay result, gene program, protein behavior, metabolite pattern, or mechanism that makes IJMS a real fit. Figure 1 should establish that molecular question early. The methods should support the mechanistic claim with enough detail for another lab to understand the assay, reagent, model, and statistical choices.

The cover letter should explain why IJMS is the right molecular-sciences audience instead of Cells, Biomolecules, Cancers, Scientific Reports, PLOS ONE, Frontiers in Molecular Biosciences, or a clinical journal. If the molecular contribution cannot carry the submission, the manuscript should be rerouted before the APC and fast-review timeline become the main decision drivers.

Check molecular science contribution weaker than the clinical or applied promise before submitting to IJMS MDPI →

Methods look complete but reproducibility details are not traceable

For manuscripts targeting International Journal of Molecular Sciences, a second pattern is a methods package that appears complete at a glance but cannot yet survive reproducibility scrutiny. The manuscript may use the MDPI template, include figures and supplementary files, and provide declarations, yet still omit reagent source details, antibody clone identifiers, cell-line authentication records, passage numbers, software versions, sequencing depth, normalization choices, exclusion criteria, statistical-test specification, or repository access.

IJMS reviewers can move quickly, which means these gaps are found quickly. A fast process helps only when the package is already disciplined.

The manuscript components should make traceability easy. The methods section should not force reviewers to infer supplier, version, dose, timing, or analytical pipeline details. Figure legends should name sample sizes and controls. Supplementary files should hold extended validation, not basic information missing from the main methods.

The data availability statement should identify concrete repositories, accession numbers, code locations, or access procedures rather than defaulting to "available on request." The references should support the exact methods used, not only the disease or pathway context. If these pieces are missing, reviewers at IJMS, Cells, Biomolecules, Scientific Reports, and PLOS ONE will all see the same weakness.

Check methods look complete but reproducibility details are not traceable before submitting to IJMS MDPI →

Special-issue speed or APC logic outruns journal-fit discipline

Across IJMS-bound manuscripts, the third pattern is a paper routed to IJMS because a special issue, fast median first-decision timeline, or institutional APC agreement made the journal attractive before the authors proved fit. The cover letter names the special issue, the abstract borrows the issue language, and the manuscript follows the template, but the study still reads as if it belongs at a narrower molecular-biology, oncology, pharmacology, bioinformatics, or applied biomedical venue.

Editors and reviewers can tell when the special issue is doing too much of the fit argument.

The practical test is to ask whether the manuscript still belongs in IJMS if the special-issue invitation disappears. If yes, the molecular-science contribution, methods, figures, data availability statement, supplementary package, and references should all make that clear. If no, the better path may be a narrower MDPI title, a society journal, Frontiers in Molecular Biosciences, Scientific Reports, or PLOS ONE depending on the evidence shape.

The cover letter should state why IJMS as a journal is right, not only why the special issue is convenient. The strongest IJMS submissions use MDPI's speed as an operational advantage after the scientific fit is already sound.

Check whether your International Journal of Molecular Sciences manuscript is submission-ready →

IJMS covers molecular science broadly, including:

• Biochemistry: Enzyme kinetics, metabolomics, protein biochemistry, lipid biology

• Molecular biology: Gene expression, RNA biology, epigenetics, molecular mechanisms

• Cell biology: Cell signaling, cell cycle, organelle biology, microscopy-based studies

• Immunology: Innate and adaptive immunity, cytokines, immune cell biology

• Structural biology: Protein structure, computational modeling, cryo-EM, NMR

• Bioinformatics: Computational methods, data analysis, database development with biological application

• Genetics and genomics: Variant analysis, population genetics, functional genomics

IJMS publishes both original research articles and reviews. Reviews are not by invitation only; you can submit unsolicited reviews if the topic fits the scope.

What IJMS doesn't publish: clinical trials, epidemiological studies, purely applied biomedical work without a molecular science component, engineering papers.

Most authors submit Research Articles. Reviews are well-suited to IJMS because the journal's broad readership benefits from accessible synthesis of a molecular topic.

IJMS uses MDPI's proprietary online submission system. The process:

1. Register at MDPI journal page (MDPI's unified submission platform)

1. Select the journal (International Journal of Molecular Sciences) and article type

1. Upload your manuscript files:

• Main manuscript (Word (.docx) or LaTeX (.tex))

• Figures (separate files at 300 dpi minimum)

• Supplementary materials (if any)

1. Complete the submission form: abstract, keywords, cover letter, author information, conflict of interest

1. Pay or confirm APC: You'll need to confirm the APC (2,900 CHF) or apply for a waiver at submission

MDPI's system checks for formatting compliance automatically. Papers that don't meet format requirements get returned for revision before editorial review.

Manuscript template: MDPI provides a Word template that applies their formatting automatically. Using the template is strongly recommended, it handles margins, fonts, heading styles, and reference formatting. Download from the IJMS author instructions page.

Sections: Introduction, Results, Discussion, Materials and Methods, Conclusions (optional but recommended), References. MDPI uses a Results + Discussion structure where the two can be combined or kept separate.

Abstract: 200 words maximum. No citations. Should summarize background, methods, key results, and significance. MDPI indexes abstracts separately, so make it keyword-rich.

Keywords: 5-10. Mix specific molecular targets with general category terms.

Figures: 300 dpi minimum. TIFF, EPS, or PNG preferred. Figures can be embedded in the main text during review. Final production will extract them separately.

Tables: In the main text. Complex tables can go in supplementary materials.

References: MDPI uses numbered references [1], [2] etc. in the text with a numbered reference list. The template handles this automatically. MDPI's reference style includes DOIs for all references.

Author contributions: Required. Use CRediT (Contributor Roles Taxonomy) format: "Conceptualization, J.S. and M.L.; Methodology, J.S.;..." etc.

Data availability statement: Required. Specify data repository (Zenodo, Figshare, Dryad, or journal-specific repository) and DOI if available. If data can't be shared, explain specifically why.

Ethics statement: Required for human subjects research (include IRB number) and animal studies (include institutional protocol number). Cell line papers should note source and authentication.

Conflict of interest statement: Required. MDPI takes COI disclosure seriously; be thorough.

MDPI's cover letter is shorter and less influential than at high-selectivity journals. It still matters for framing. Include:

1. Article type and title

2.2-3 sentences on what the paper shows and why it's novel

1. Confirmation that the paper is not under consideration elsewhere

1. APC payment confirmation or waiver request reason

The cover letter won't rescue a paper outside scope, but a clear cover letter helps editors route your paper to an appropriate academic editor quickly.

IJMS does desk-reject papers, though at a lower rate than higher-impact journals. Common desk rejection triggers:

• Out of scope. Clinical endpoints without a molecular science component, engineering papers, or pure computational work without biological context.

• Incomplete methodology. Missing reagent details, cell line authentication, antibody clone information, or statistical methods.

• Missing ethical documentation. Human samples or animal work without the required ethics statement and approval numbers.

• No data availability statement. MDPI enforces this rigorously; missing it gets the paper returned immediately.

• Obvious methodological problems. Underpowered studies, statistical errors visible from the abstract, or claims that dramatically overreach the data.

IJMS charges 2,900 CHF (approximately $3,200 USD at 2026 rates). This is paid after acceptance, not at submission.

Waivers are available for:

• Authors from low-income countries (automatic full waiver)

• Authors with documented financial hardship (partial or full waiver on application)

• Authors whose institutions have MDPI agreements (check MDPI's institutional membership list)

Apply for a waiver at submission by selecting the waiver option in the submission form. MDPI reviews these quickly.

IJMS's editorial process is fast. You'll typically hear within a few days whether the paper is moving to external review. Once in review, expect a decision in 15-30 days total. For the full timeline breakdown, see IJMS review time.

After acceptance, MDPI's production process is extremely fast. Papers go live with a DOI within 3-5 days of final acceptance.

For IJMS-targeted manuscripts, three patterns consistently predict desk-screen failure at International Journal of Molecular Sciences. The patterns below are the same ones the journal's handling editors and outside reviewers flag at first-pass triage.

Scope-fit ambiguity in the abstract. IJMS editors move fastest on manuscripts whose contribution is obviously aligned with molecular biology research with reproducible methodology and adequate statistical power. The named failure pattern: underpowered experiments (nless than 3) without justification get extended methodology revision. Check whether your abstract reads to IJMS's scope

Methods package incomplete for the journal's reviewer pool. IJMS reviewers expect specific methodological detail. Missing statistical-test specification extends reviewer assignment. Check if your methods package is reviewer-complete

Reference-list and clean-citation failure mode. Editorial team at International Journal of Molecular Sciences screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch

Editorial evidence signal for International Journal of Molecular Sciences. Our review of public author guidance, recent published article packages, and Manusights pre-submission review patterns points to this practical risk: Ijms reviewers consistently flag underpowered experiments (nless than 3) and missing statistical-test specification; rapid review-time depends on methodology completeness. Treat this as a fit-and-artifact screen rather than a private outcome claim; official journal pages remain authoritative for submission mechanics and policy requirements.

IJMS is Q1 in Biochemistry and Molecular Biology (rank 72/319, JCR 2024), but context matters. The journal published 10,013 articles in a single year, that's one of the highest volumes of any Q1 journal. The IF of 4.9 and JCI of 0.71 reflect that volume.

What this means practically: IJMS is a legitimate, indexed, Q1 venue with fast turnaround and broad scope. It's not a prestige journal. If you need a reliable publication with a real JIF and don't need the signaling power of a lower-volume, higher-selectivity title, IJMS is a solid choice.

Choose IJMS if you need fast publication (15-30 days to decision), you're comfortable with the 2,900 CHF APC, your work is molecular-science-focused, and you value Q1 indexing over selectivity signaling.

Think twice if your field views high-volume MDPI journals skeptically, you're building a tenure case where selectivity perception matters, or a society journal in your subdiscipline would carry more weight with reviewers who'll read your CV.

Last verified against MDPI author guidelines and Clarivate JCR 2024 (JIF 4.9, JCI 0.71, Q1, rank 72/319 in Biochemistry and Molecular Biology).

For manuscripts targeting International Journal of Molecular Sciences, five patterns generate the most consistent desk rejections worth knowing before submission.

• Out-of-scope submission without a molecular science component. The IJMS author guidelines define the journal's scope as biochemistry, molecular biology, cell biology, immunology, structural biology, bioinformatics, and genetics, explicitly excluding clinical trials, epidemiological studies, purely applied biomedical work, and engineering papers without a molecular science component.

Manusights pre-submission pattern analysis shows many desk rejections involve manuscripts that study disease endpoints or biological systems without connecting findings to a molecular mechanism, pathway, or structural biology insight that would interest the journal's molecular science readership. Editors specifically screen for manuscripts where the molecular science component is central to the contribution, not peripheral to an applied or clinical question.

• Incomplete methodology missing reagent details or authentication. The same pattern analysis often finds many submissions arrive with methods sections that do not include the reagent source details, cell line authentication records, antibody clone identifiers, or statistical methods specification that MDPI's editorial standards require for molecular biology and cell biology manuscripts. In practice, editors consistently return manuscripts where key methodological information is missing before sending them for peer review, because incomplete methods prevent reproducibility assessment and are treated as evidence of inadequate preparation rather than as a revision request.

• Missing data availability statement or ethics documentation. A related pattern is that many submissions are returned at the initial screening stage because the data availability statement does not specify the repository and access procedures for supporting data, or because human subjects or animal research sections do not include the required IRB approval number, institutional protocol number, or ethics statement required by MDPI.

In our analysis of submission difficulties at IJMS, this pattern is most common in submissions from authors unfamiliar with MDPI's mandatory compliance requirements, where these items are enforced before any scientific review begins.

• Conclusions overreach the molecular evidence in the submitted study. A related pattern is that many submissions frame mechanistic, causal, or clinical conclusions from molecular correlations, single-model experiments, or underpowered studies that do not support the interpretive claims being made. Editors consistently screen for manuscripts where the conclusions are proportionate to the molecular evidence type and the study design, because overreach from single-assay or single-cohort data to broad mechanistic conclusions is among the most common reviewer objections at journals in this tier.

• Cover letter too generic to confirm journal fit or APC payment plan. A related pattern is that many submissions arrive with cover letters that describe the research area and findings without confirming that the work fits IJMS's molecular science scope, acknowledging the 2,900 CHF APC, or indicating whether a waiver application is being submitted. Editors explicitly consider whether the cover letter confirms scope fit and APC awareness before routing the paper through the editorial system.

Before submitting to International Journal of Molecular Sciences, an IJMS submission readiness check identifies whether your methodology, scope alignment, and documentation meet the editorial bar before you commit to the submission.

Or see example reports before you finalize.